= 0.049]. The promising long-term survival produced by the sequential treatment module deserves further phase II evaluation.
No takes yet. Share an insight, caveat, or question.
Correale et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: